Conquer is a phase 1 clinical study to test the safety and efficacy of a new therapy called AM712 to treat Neovascular Age-related Macular Degeneration (nAMD). The study wants to see the drug’s efficacy in stabilizing the abnormal growth of blood vessels in the center region of the retina. Participants will enroll in the study for 16 weeks with a total of 11 visits.

This clinical trial aims to observe how intermediate age-related macular degeneration (iAMD) progresses to advanced stages of the disease. No treatment will be given in the study as the main goal of the study is to learn more about iAMD. Participants enrollment will last about 3 years with 12 follow up visits every 12 weeks.

To be eligible, participants must be between 50 and 95 years old with iAMD.

The OnwarD study tests a new medicine for adults with an advanced form of dry AMD called geographic atrophy (GA). The study drug is called danicopan, an oral tablet taken once or twice a day.Participants will be enrolled in the study for up to 2 years and 3 months. In the first year, participants will take either the medicine or a placebo but only the medicine in the second year.

To be eligible, participants must be 60 years or older nad have dry AMD in at least one eye.

This study aims to compare the effectiveness of different approved drugs for preventing macular edema after cataract surgery. Participants are assigned to either receive steroid or anti-VEGF injections. After their cataract surgery, the patients will come to the clinic once a month for follow up visits for 3 months. The study is not experimental, so insurance will be billed for all examinations, treatments, and medications.

To be eligible for the study, participants must be at least 18 years of age with a diagnosis of Type 1 or 2 Diabetes.

This study aims to identify and study patients as well as their affected family members with an uncommon eye disorder called Macular Telangiectasia Type 2 (MacTel Type 2). The study’s goal is to create a registry to help current study participants and may be used in the future to help find a way to prevent or treat the disease. Participation includes one visit to the clinic and if you agree, we will contact you at least once a year by phone, to check on your health.

To be eligible, you must be 18 years of age or older and have a clinical diagnosis of MacTel Type 2 at the study site.

This study is designed to evaluate a new drug’s safety and effectiveness for the treatment of diabetic macular edema (DME) in combination with ranibizumab. The drug is expected to inhibit molecules that contribute to inflammation and will be compared to ranibizumab, one of the standard treatments for DME. The study duration is up to 72 weeks with visits every month.

To be eligible for the study, participants must be at least 18 years of age or older, have been diagnosed with Type 1/2 Diabetes and DME associated with Diabetic Retinopathy.

This study is designed to evaluate a new drug’s safety and effectiveness for the treatment of diabetic macular edema (DME). The drug is expected to inhibit molecules that contribute to inflammation and will be compared to ranibizumab, one of the standard treatments for DME. The study duration is up to 72 weeks with visits every month.

To be eligible for the study, participants must be at least 18 years of age or older, have been diagnosed with Type 1/2 Diabetes and DME associated with Diabetic Retinopathy, and willing to allow Aqueous Humor collection

The purpose of this study is to investigate the effects (good or bad) of R07497372, the study drug, in participants with Diabetic Macular Edema (DME). In this study, you will get the study drug. Over 36 weeks, you will receive a total of 3 injections every 4 weeks throughout the study.

You may be eligible if at least 18 years of age or older, have been diagnosed with Type 1/2 Diabetes and DME associated with Diabetic Retinopathy.

This study offers a new gene-therapy drug that has potential to treat geographic atrophy secondary to age-related macular degeneration. Participants will be asked to attend 13 clinic visits over 18 months for health and eye exams.

Potentially eligible if 60 years or older and diagnosed with geographic atrophy.

The study offers a potential new treatment option for individuals with wet age-related macular degeneration (wAMD) by investigating the safety and effectiveness of an investigational drug named EYP-1901. The drug is designed to potentially block the proteins that cause wAMD and will be compared to aflibercept, an approved treatment for wAMD. Participants are required to visit the study center at least 16 times over approximately 59 weeks. Participants will be randomly assigned to receive either EYP-1901 or aflibercept, with a 67% chance of receiving EYP-1901.

To be eligible for the study, participants must be at least 50 years of age or older, have been diagnosed with wAMD, and have received previous eye injection treatments for wAMD.

We now offer a new, potentially easier treatment option for people with diabetic retinopathy by testing the safety and effectiveness of eye drop medication. With only 8 visits required over 6 months and the ability to administer the drops at home, it could be a more convenient alternative to injections. To be eligible for the study, participants must be at least 18 years of age or older, have been diagnosed with Type 1 or 2 Diabetes and have had no previous eye injections or laser treatments for diabetic retinopathy.

We now offer a new, potentially easier treatment option for people with diabetic retinopathy by testing the safety and effectiveness of eye drop medication. With only 8 visits required over 6 months and the ability to administer the drops at home, it could be a more convenient alternative to injections.

To be eligible for the study, participants must be at least 18 years of age or older, have been diagnosed with Type 1 or 2 Diabetes and have had no previous eye injections or laser treatments for diabetic retinopathy.